Current position of 5HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics

This publication has 28 references indexed in Scilit:

• Prevention of cisplatin‐induced acute and delayed emesis by the selective neurokinin‐1 antagonists, L‐758,298 and MK‐869
  Cancer, 2002
• Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist
  New England Journal of Medicine, 1999
• Consensus proposal for 5HT 3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy
  Supportive Care in Cancer, 1998
• Optimal Control of Acute Cisplatin-lnduced Emesis
  Oncology, 1996
• The anti‐emetic effects of CP‐99,994 in the ferret and the dog: role of the NK₁ receptor
  British Journal of Pharmacology, 1995
• Ondansetron Compared with Granisetron in the Prophylaxis of Cyclophosphamide-lnduced Emesis in Out-Patients: A Multicentre, Double-Blind, Double-Dummy, Randomised, Parallel-Group Study
  Oncology, 1995
• Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron.
  British Journal of Clinical Pharmacology, 1994
• Ondansetron Compared with Granisetron in the Prophylaxis of Cisplatin-lnduced Acute Emesis: A Multicentre Double-Blind, Randomised, Parallel-Group Study
  Oncology, 1994
• Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy
  The Lancet, 1991
• On the receiving end—patient perception of the side-effects of cancer chemotherapy
  European Journal of Cancer and Clinical Oncology, 1983